282 related articles for article (PubMed ID: 23864346)
1. Kidney volume and function in autosomal dominant polycystic kidney disease.
Higashihara E; Nutahara K; Okegawa T; Shishido T; Tanbo M; Kobayasi K; Nitadori T
Clin Exp Nephrol; 2014 Feb; 18(1):157-65. PubMed ID: 23864346
[TBL] [Abstract][Full Text] [Related]
2. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
[TBL] [Abstract][Full Text] [Related]
3. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
4. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
[TBL] [Abstract][Full Text] [Related]
5. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF; Bennett WM; Chapman AB;
Kidney Int; 2018 Mar; 93(3):691-699. PubMed ID: 29290310
[TBL] [Abstract][Full Text] [Related]
6. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
[TBL] [Abstract][Full Text] [Related]
7. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
Nakajima A; Lu Y; Kawano H; Horie S; Muto S
Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
[TBL] [Abstract][Full Text] [Related]
8. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
Coban M; Inci A
Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
[TBL] [Abstract][Full Text] [Related]
9. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease.
Chen D; Ma Y; Wang X; Yu S; Li L; Dai B; Mao Z; Sun L; Xu C; Rong S; Tang M; Zhao H; Liu H; Serra AL; Graf N; Liu S; Wüthrich RP; Mei C
PLoS One; 2014; 9(3):e92232. PubMed ID: 24651850
[TBL] [Abstract][Full Text] [Related]
11. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
[TBL] [Abstract][Full Text] [Related]
12. A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease.
Simms RJ; Doshi T; Metherall P; Ryan D; Wright P; Gruel N; van Gastel MDA; Gansevoort RT; Tindale W; Ong ACM
Eur Radiol; 2019 Aug; 29(8):4188-4197. PubMed ID: 30666443
[TBL] [Abstract][Full Text] [Related]
13. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
Kim K; Trott JF; Gao G; Chapman A; Weiss RH
BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
[TBL] [Abstract][Full Text] [Related]
14. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
Higashihara E; Torres VE; Chapman AB; Grantham JJ; Bae K; Watnick TJ; Horie S; Nutahara K; Ouyang J; Krasa HB; Czerwiec FS;
Clin J Am Soc Nephrol; 2011 Oct; 6(10):2499-507. PubMed ID: 21903984
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
Clin J Am Soc Nephrol; 2007 Jan; 2(1):112-20. PubMed ID: 17699395
[TBL] [Abstract][Full Text] [Related]
16. Correlations between renal function and the total kidney volume measured on imaging for autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.
Jo WR; Kim SH; Kim KW; Suh CH; Kim JK; Kim H; Lee JG; Oh WY; Choi SE; Pyo J
Eur J Radiol; 2017 Oct; 95():56-65. PubMed ID: 28987699
[TBL] [Abstract][Full Text] [Related]
17. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
[TBL] [Abstract][Full Text] [Related]
18. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
[TBL] [Abstract][Full Text] [Related]
19. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
[TBL] [Abstract][Full Text] [Related]
20. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
